. Author manuscript; available in PMC: 2017 Aug 21.

Published in final edited form as: Curr Radiopharm. 2011 Oct;4(4):306–320. doi: 10.2174/1874471011104040306

Table I.

Comparison of the cytotoxicity in vitro of ²²⁵Ac- versus ²¹³Bi-antibody constructs.

Antibody	²²⁵Ac construct ED₅₀ (pCi/mL)	²¹³Bi construct ED₅₀ (pCi/mL)	Cancer	Cell type
HuM195	8	-	AML	HL60
HuM195	-	200,000	AML	HL60
B4	60	-	B-NHL	Daudi
B4	-	280,000	B-NHL	Daudi
J591	90	-	Prostate Carcinoma	LNCaP
J591	-	220,000	Prostate Carcinoma	LNCaP
3F8	100	-	Neuroblastoma	NMB7
Herceptin	150	-	Breast Carcinoma	BT-474
Herceptin	1300	-	Ovarian Carcinoma	SKOV3-NMP2

ED₅₀ was measured by [³H]thymidine uptake assay [6].